Daiichi Sankyo has inaugurated its permanent Canadian headquarters in Toronto, marking a strategic escalation in the Japanese drugmaker’s North American oncology push. The move is designed to accelerate the delivery of its cancer therapies and deepen its operational footprint in Canada’s healthcare ecosystem, supporting 18 clinical trials across 43 specialized sites nationwide.

The expansion aligns with Ontario’s efforts to attract high-value life sciences investment and reduce corporate overhead. Local officials, including Premier Doug Ford, framed the investment as a win for the provincial economy and workforce, reinforcing Toronto’s status as a global hub for biomedical innovation and research collaboration.

For Daiichi Sankyo, establishing a permanent base in Toronto is critical for navigating Canada’s regulatory and healthcare complexities. The company’s leadership emphasized the commitment to local patients and partners, viewing the headquarters as a milestone in its global expansion and a platform to broaden access to its oncology portfolio.